These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 24638011)

  • 1. Diagnostic challenges of clonal heterogeneity in prostate cancer.
    Haffner MC; De Marzo AM; Yegnasubramanian S; Epstein JI; Carter HB
    J Clin Oncol; 2015 Mar; 33(7):e38-40. PubMed ID: 24638011
    [No Abstract]   [Full Text] [Related]  

  • 2. Will active surveillance for clinically localized prostate cancer survive in the era of individualized medicine?
    Gandaglia G; Giannarini G; Suardi N; Montorsi F; Briganti A
    Eur Urol; 2014 Aug; 66(2):186-7. PubMed ID: 24836154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is undetectable prostate-specific antigen always reliable to rule out prostate cancer recurrence after radical prostatectomy?
    Schriefer P; Steurer S; Huland H; Graefen M
    J Clin Oncol; 2012 Nov; 30(32):e341-4. PubMed ID: 23032622
    [No Abstract]   [Full Text] [Related]  

  • 4. Active surveillance monitoring: the role of novel biomarkers and imaging.
    Ward JF; Eggener SE
    Asian J Androl; 2015; 17(6):882-4; discussion 883. PubMed ID: 26112488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prostate cancer histoseminar: Update of the 2016 WHO classification - case No. 8: Acinar prostatic adenocarcinoma, Gleason score 6 (3+3)].
    Ferlicot S
    Ann Pathol; 2017 Jun; 37(3):259-263. PubMed ID: 28522121
    [No Abstract]   [Full Text] [Related]  

  • 6. The dilemma of prostate-specific antigen testing.
    Leach R; Thompson IM
    Arch Intern Med; 2012 Jun; 172(11):835-6. PubMed ID: 22905350
    [No Abstract]   [Full Text] [Related]  

  • 7. Transrectal ultrasound-guided biopsy of prostate voxels identified as suspicious of malignancy on three-dimensional (1)H MR spectroscopic imaging in patients with abnormal digital rectal examination or raised prostate specific antigen level of 4-10 ng/ml.
    Kumar V; Jagannathan NR; Kumar R; Thulkar S; Gupta SD; Hemal AK; Gupta NP
    NMR Biomed; 2007 Feb; 20(1):11-20. PubMed ID: 16894640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regular transition zone biopsy during active surveillance for prostate cancer may improve detection of pathological progression.
    Wong LM; Toi A; Van der Kwast T; Trottier G; Alibhai SM; Timilshina N; Evans A; Zlotta A; Fleshner N; Finelli A
    J Urol; 2014 Oct; 192(4):1088-93. PubMed ID: 24742593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrence of prostate adenocarcinoma presenting with multiple myeloma simulating skeletal metastases of prostate adenocarcinoma.
    Huang E; Teh BS; Saleem A; Butler EB
    Urology; 2002 Dec; 60(6):1111. PubMed ID: 12475684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges and recommendations for early identification of metastatic disease in prostate cancer.
    Crawford ED; Stone NN; Yu EY; Koo PJ; Freedland SJ; Slovin SF; Gomella LG; Berger ER; Keane TE; Sieber P; Shore ND; Petrylak DP;
    Urology; 2014 Mar; 83(3):664-9. PubMed ID: 24411213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Diagnostic value of tissue and serum prostate specific antigen in prostate cancer].
    Medvedev VL
    Voen Med Zh; 2004 Feb; 325(2):50-4. PubMed ID: 15101295
    [No Abstract]   [Full Text] [Related]  

  • 12. ERG protein expression in diagnostic specimens is associated with increased risk of progression during active surveillance for prostate cancer.
    Berg KD; Vainer B; Thomsen FB; Røder MA; Gerds TA; Toft BG; Brasso K; Iversen P
    Eur Urol; 2014 Nov; 66(5):851-60. PubMed ID: 24630684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Active surveillance of low risk prostate cancer].
    Weißbach L
    Urologe A; 2015 Jun; 54(6):869-70. PubMed ID: 26081819
    [No Abstract]   [Full Text] [Related]  

  • 14. Prostate Biopsy in Men with an Elevated PSA Level - Reducing Overdiagnosis.
    Pinsky PF
    N Engl J Med; 2024 Sep; 391(12):1153-1154. PubMed ID: 39321368
    [No Abstract]   [Full Text] [Related]  

  • 15. Prostate cancer imaging.
    Kundra V
    Semin Roentgenol; 2006 Apr; 41(2):139-49. PubMed ID: 16697892
    [No Abstract]   [Full Text] [Related]  

  • 16. [Reply].
    Lellig K; Buchner A; Stief C
    Urologe A; 2015 Jun; 54(6):870. PubMed ID: 26280043
    [No Abstract]   [Full Text] [Related]  

  • 17. Clonal evaluation of prostate cancer foci in biopsies with discontinuous tumor involvement by dual ERG/SPINK1 immunohistochemistry.
    Fontugne J; Davis K; Palanisamy N; Udager A; Mehra R; McDaniel AS; Siddiqui J; Rubin MA; Mosquera JM; Tomlins SA
    Mod Pathol; 2016 Feb; 29(2):157-65. PubMed ID: 26743468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Active surveillance for prostate cancer: when to recommend delayed intervention.
    Babaian KN
    Asian J Androl; 2015; 17(6):885-7; discussion 886-7. PubMed ID: 26178391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostatic carcinoma.
    Lawton CA; Grignon D; Newhouse JH; Schellhammer PF; Kuban DA
    Radiographics; 1999; 19(1):185-203. PubMed ID: 9925399
    [No Abstract]   [Full Text] [Related]  

  • 20. [Prostate cancer histoseminar: Update of the 2016 WHO classification - case n
    Compérat E
    Ann Pathol; 2017 Jun; 37(3):228-231. PubMed ID: 28554777
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 24.